XML 169 R112.htm IDEA: XBRL DOCUMENT
v3.25.0.1

Goodwill and other intangible assets - Detailed Information for Principal Marketed Products (Details) - EUR (€) € in Millions | 12 Months Ended |
--- | --- | ---
Dec. 31, 2024 | Dec. 31, 2023 | Dec. 31, 2022
Disclosure of detailed information about intangible assets [line items] |  |  |  |
Other intangible assets |  | € 22,629 | € 24,319 | € 21,640
Marketed products |  |  |  |
Disclosure of detailed information about intangible assets [line items] |  |  |  |
Concentration risk percentage |  | 95.00% |  |
Other intangible assets |  | € 12,700 | € 16,600 | 12,700
Useful life, intangible assets other than goodwill (in years) |  |  | 10 years |
Total: principal marketed products incl. Opella products presented in "Assets held for sale" |  |  |  |
Disclosure of detailed information about intangible assets [line items] |  |  |  |
Other intangible assets |  | 14,795 | € 15,927 | 11,863
Intangible Assets Other Than Goodwill, Discontinued Operations |  | 12,002 | 13,055 | 9,429
Genzyme |  |  |  |
Disclosure of detailed information about intangible assets [line items] |  |  |  |
Other intangible assets | [1] | € 59 | 208 | 621
Useful life, intangible assets other than goodwill (in years) | [1],[2] | 10 years |  |
Remaining amortisation period of intangible assets material to entity | [1],[3] | 2 years |  |
Boehringer Ingelheim Consumer Healthcare |  |  |  |
Disclosure of detailed information about intangible assets [line items] |  |  |  |
Other intangible assets | [1] | € 1,764 | 1,806 | 2,037
Useful life, intangible assets other than goodwill (in years) | [1],[2] | 17 years |  |
Remaining amortisation period of intangible assets material to entity | [1],[3] | 10 years |  |
Aventis |  |  |  |
Disclosure of detailed information about intangible assets [line items] |  |  |  |
Other intangible assets | [1] | € 39 | 43 | 58
Useful life, intangible assets other than goodwill (in years) | [1],[2] | 9 years |  |
Remaining amortisation period of intangible assets material to entity | [1],[3] | 10 years |  |
Chattem |  |  |  |
Disclosure of detailed information about intangible assets [line items] |  |  |  |
Other intangible assets | [1] | € 482 | 501 | 574
Useful life, intangible assets other than goodwill (in years) | [1],[2] | 23 years |  |
Remaining amortisation period of intangible assets material to entity | [1],[3] | 10 years |  |
Protein Sciences |  |  |  |
Disclosure of detailed information about intangible assets [line items] |  |  |  |
Other intangible assets | [1] | € 381 | 420 | 498
Useful life, intangible assets other than goodwill (in years) | [1],[2] | 13 years |  |
Remaining amortisation period of intangible assets material to entity | [1],[3] | 6 years |  |
Ablynx |  |  |  |
Disclosure of detailed information about intangible assets [line items] |  |  |  |
Other intangible assets | [1] | € 1,083 | 1,220 | 1,357
Useful life, intangible assets other than goodwill (in years) | [1],[2] | 14 years |  |
Remaining amortisation period of intangible assets material to entity | [1],[3] | 8 years |  |
Bioverativ |  |  |  |
Disclosure of detailed information about intangible assets [line items] |  |  |  |
Other intangible assets | [1] | € 4,349 | 5,152 | 4,836
Useful life, intangible assets other than goodwill (in years) | [1],[2] | 13 years |  |
Remaining amortisation period of intangible assets material to entity | [1],[3] | 8 years |  |
Rezurock |  |  |  |
Disclosure of detailed information about intangible assets [line items] |  |  |  |
Other intangible assets |  | € 1,513 | 1,580 | 1,702
Useful life, intangible assets other than goodwill (in years) | [2] | 12 years |  |
Remaining amortisation period of intangible assets material to entity | [3] | 9 years |  |
Tzield |  |  |  |
Disclosure of detailed information about intangible assets [line items] |  |  |  |
Other intangible assets |  | € 2,339 | 2,405 | 0
Useful life, intangible assets other than goodwill (in years) | [2] | 12 years |  |
Remaining amortisation period of intangible assets material to entity | [3] | 11 years |  |
Beyfortus |  |  |  |
Disclosure of detailed information about intangible assets [line items] |  |  |  |
Other intangible assets |  | € 2,087 | 1,870 | 180
Useful life, intangible assets other than goodwill (in years) | [2] | 17 years |  |
Remaining amortisation period of intangible assets material to entity | [3] | 16 years |  |
Qunol |  |  |  |
Disclosure of detailed information about intangible assets [line items] |  |  |  |
Other intangible assets |  | € 699 | € 722 | € 0
Useful life, intangible assets other than goodwill (in years) | [2] | 10 years |  |
Remaining amortisation period of intangible assets material to entity | [3] | 8 years |  |
Gross value | Total: principal marketed products incl. Opella products presented in "Assets held for sale" |  |  |  |
Disclosure of detailed information about intangible assets [line items] |  |  |  |
Other intangible assets |  | € 68,753 |  |
Intangible Assets Other Than Goodwill, Discontinued Operations |  | 60,214 |  |
Gross value | Genzyme |  |  |  |
Disclosure of detailed information about intangible assets [line items] |  |  |  |
Other intangible assets | [1] | 10,600 |  |
Gross value | Boehringer Ingelheim Consumer Healthcare |  |  |  |
Disclosure of detailed information about intangible assets [line items] |  |  |  |
Other intangible assets | [1] | 3,520 |  |
Gross value | Aventis |  |  |  |
Disclosure of detailed information about intangible assets [line items] |  |  |  |
Other intangible assets | [1] | 34,175 |  |
Gross value | Chattem |  |  |  |
Disclosure of detailed information about intangible assets [line items] |  |  |  |
Other intangible assets | [1] | 1,406 |  |
Gross value | Protein Sciences |  |  |  |
Disclosure of detailed information about intangible assets [line items] |  |  |  |
Other intangible assets | [1] | 886 |  |
Gross value | Ablynx |  |  |  |
Disclosure of detailed information about intangible assets [line items] |  |  |  |
Other intangible assets | [1] | 1,966 |  |
Gross value | Bioverativ |  |  |  |
Disclosure of detailed information about intangible assets [line items] |  |  |  |
Other intangible assets | [1] | 8,375 |  |
Gross value | Rezurock |  |  |  |
Disclosure of detailed information about intangible assets [line items] |  |  |  |
Other intangible assets |  | 2,033 |  |
Gross value | Tzield |  |  |  |
Disclosure of detailed information about intangible assets [line items] |  |  |  |
Other intangible assets |  | 2,714 |  |
Gross value | Beyfortus |  |  |  |
Disclosure of detailed information about intangible assets [line items] |  |  |  |
Other intangible assets |  | 2,288 |  |
Gross value | Qunol |  |  |  |
Disclosure of detailed information about intangible assets [line items] |  |  |  |
Other intangible assets |  | 790 |  |
Accumulated amortization & impairment | Total: principal marketed products incl. Opella products presented in "Assets held for sale" |  |  |  |
Disclosure of detailed information about intangible assets [line items] |  |  |  |
Other intangible assets |  | (53,958) |  |
Intangible Assets Other Than Goodwill, Discontinued Operations |  | (48,212) |  |
Accumulated amortization & impairment | Genzyme |  |  |  |
Disclosure of detailed information about intangible assets [line items] |  |  |  |
Other intangible assets | [1] | (10,541) |  |
Accumulated amortization & impairment | Boehringer Ingelheim Consumer Healthcare |  |  |  |
Disclosure of detailed information about intangible assets [line items] |  |  |  |
Other intangible assets | [1] | (1,756) |  |
Accumulated amortization & impairment | Aventis |  |  |  |
Disclosure of detailed information about intangible assets [line items] |  |  |  |
Other intangible assets | [1] | (34,136) |  |
Accumulated amortization & impairment | Chattem |  |  |  |
Disclosure of detailed information about intangible assets [line items] |  |  |  |
Other intangible assets | [1] | (924) |  |
Accumulated amortization & impairment | Protein Sciences |  |  |  |
Disclosure of detailed information about intangible assets [line items] |  |  |  |
Other intangible assets | [1] | (505) |  |
Accumulated amortization & impairment | Ablynx |  |  |  |
Disclosure of detailed information about intangible assets [line items] |  |  |  |
Other intangible assets | [1] | (883) |  |
Accumulated amortization & impairment | Bioverativ |  |  |  |
Disclosure of detailed information about intangible assets [line items] |  |  |  |
Other intangible assets | [1] | (4,026) |  |
Accumulated amortization & impairment | Rezurock |  |  |  |
Disclosure of detailed information about intangible assets [line items] |  |  |  |
Other intangible assets |  | (520) |  |
Accumulated amortization & impairment | Tzield |  |  |  |
Disclosure of detailed information about intangible assets [line items] |  |  |  |
Other intangible assets |  | (375) |  |
Accumulated amortization & impairment | Beyfortus |  |  |  |
Disclosure of detailed information about intangible assets [line items] |  |  |  |
Other intangible assets |  | (201) |  |
Accumulated amortization & impairment | Qunol |  |  |  |
Disclosure of detailed information about intangible assets [line items] |  |  |  |
Other intangible assets |  | € (91) |  |
Bottom of range |  |  |  |
Disclosure of detailed information about intangible assets [line items] |  |  |  |
Useful life, intangible assets other than goodwill (in years) |  | 1 year |  |
Top of range |  |  |  |
Disclosure of detailed information about intangible assets [line items] |  |  |  |
Useful life, intangible assets other than goodwill (in years) |  | 25 years |  |
[1] | (c)Commercialized products derived from the acquisition of these companies. In the case of Bioverativ, the product Enjaymo was sold to Recordati in 2024 (see Note D.1.).
[2] | (a)Weighted averages. The amortization periods for these products vary between 1 and 25 years.
[3] | (b)Weighted averages.

X
- Definition Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table. + References No definition available. + Details
Name: | ifrs-full_DisclosureOfIntangibleAssetsLineItems
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The amount of identifiable non-monetary assets without physical substance. This amount does not include goodwill. [Refer: Goodwill] + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IAS -Number 38 -IssueDate 2023-01-01 -Paragraph 118 -Subparagraph e -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2023-en-r&anchor=para_118_e&doctype=Standard -URIDate 2023-03-23 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Name IAS -Number 1 -IssueDate 2023-01-01 -Paragraph 54 -Subparagraph c -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_54_c&doctype=Standard -URIDate 2023-03-23 + Details
Name: | ifrs-full_IntangibleAssetsOtherThanGoodwill
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition The remaining amortisation period of individual intangible assets that are material to the entity’s financial statements. [Refer: Depreciation and amortisation expense] + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IAS -Number 38 -IssueDate 2023-01-01 -Paragraph 122 -Subparagraph b -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2023-en-r&anchor=para_122_b&doctype=Standard -URIDate 2023-03-23 + Details
Name: | ifrs-full_RemainingAmortisationPeriodOfIntangibleAssetsMaterialToEntity2019
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition The useful life, measured as period of time, used for intangible assets other than goodwill. [Refer: Intangible assets other than goodwill] + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IAS -Number 38 -IssueDate 2023-01-01 -Paragraph 118 -Subparagraph a -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2023-en-r&anchor=para_118_a&doctype=Standard -URIDate 2023-03-23 + Details
Name: | ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Concentration risk threshold percentage. + References No definition available. + Details
Name: | sny_ConcentrationRiskThresholdPercentage
Namespace Prefix: | sny_
Data Type: | dtr-types1:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Intangible Assets Other Than Goodwill, Discontinued Operations + References No definition available. + Details
Name: | sny_IntangibleAssetsOtherThanGoodwillDiscontinuedOperations
Namespace Prefix: | sny_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Details
Name: | ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=sny_MarketedProductsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=sny_PrincipalMarketedProductsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=sny_PrincipalMarketedProductsGenzymeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=sny_PrincipalMarketedProductsBoehringeringelheimConsumerHealthcareMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=sny_PrincipalMarketedProductsAventisMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=sny_PrincipalMarketedProductsChattemMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=sny_PrincipalMarketedProductsProteinSciencesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=sny_PrincipalMarketedProductsAblynxMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=sny_PrincipalMarketedProductsBioverativMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=sny_PrincipalMarketedProductsRezurockMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=sny_PrincipalMarketedProductsTZIELDMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=sny_PrincipalMarketedProductsBeyfortusMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=sny_PrincipalMarketedProductsQunolMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |